Takeda Pharmaceutical (TAK) Shares Outstanding (2017 - 2026)
Takeda Pharmaceutical (TAK) posted quarterly Shares Outstanding (Entity) of $143.2 million for Q1 2026, up 15.51% year-over-year from $124.0 million in Q1 2025, and up 16.08% quarter-over-quarter from $123.4 million in Q3 2025.
Takeda Pharmaceutical (TAK) Shares Outstanding (2017 - 2026) Analysis & Trends
Takeda Pharmaceutical's Shares Outstanding (Entity) history runs 10 years deep, the most recent figure standing at $143.2 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 15.51% year-over-year to $143.2 million; the TTM figure through Mar 2026 stood at $143.2 million (up 15.51% YoY), while the FY2026 annual figure was $143.2 million, up 15.51% from the prior year.
- Shares Outstanding (Entity) for Q1 2026 stood at $143.2 million, up from $123.4 million in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $143.2 million in Q1 2026, with the low at $115.4 million in Q2 2022.
- The 5-year median for Shares Outstanding (Entity) is $123.4 million (2025), against an average of $127.3 million.
- The sharpest annual moves came in 2022 and 2023: Shares Outstanding (Entity) dropped 26.67% in 2022, then rose 21.47% in 2023.
- Takeda Pharmaceutical's Shares Outstanding (Entity) stood at $116.0 million in 2022, then rose by 21.47% to $140.9 million in 2023, then retreated by 14.34% to $120.7 million in 2024, then advanced by 2.19% to $123.4 million in 2025, then gained by 16.08% to $143.2 million in 2026.
- Business Quant data shows TAK's Shares Outstanding (Entity) at $143.2 million in Q1 2026, $123.4 million in Q3 2025, and $124.0 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.85 Bn | 42.88 Bn | - | 4.44 Bn |
| 2 | Teva Pharmaceutical Industries | 43.31 Bn | 39.66 Bn | 2.15 Bn | 1.17 Bn |
| 3 | Zoetis | 31.65 Bn | 29.98 Bn | 1.05 Bn | 417.60 Mn |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | 1.58 Bn |
| 5 | United Therapeutics | 22.18 Bn | 19.52 Bn | 683.80 Mn | 42.60 Mn |
| 6 | Viatris | 18.82 Bn | 17.94 Bn | 1.46 Bn | 1.16 Bn |
| 7 | Neurocrine Biosciences | 15.70 Bn | 15.31 Bn | 935.80 Mn | 101.00 Mn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | 499.50 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | 832.44 Mn |
| 10 | Alkermes | 8.21 Bn | 7.55 Bn | 397.90 Mn | 167.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.58 Bn |
| Mar 31, 2026 | 1.58 Bn |
| Dec 31, 2025 | 1.57 Bn |
| Sep 30, 2025 | 1.57 Bn |
| Jun 30, 2025 | 1.58 Bn |
| Mar 31, 2025 | 1.58 Bn |
| Dec 31, 2024 | 1.58 Bn |
| Sep 30, 2024 | 1.58 Bn |
| Jun 30, 2024 | 1.56 Bn |
| Mar 31, 2024 | 1.56 Bn |
| Dec 31, 2023 | 1.57 Bn |
| Sep 30, 2023 | 1.57 Bn |
| Jun 30, 2023 | 1.55 Bn |
| Mar 31, 2023 | 1.55 Bn |
| Dec 31, 2022 | 1.55 Bn |
| Sep 30, 2022 | 1.55 Bn |
| Jun 30, 2022 | 1.55 Bn |
| Mar 31, 2022 | 1.56 Bn |
| Dec 31, 2021 | 1.57 Bn |
| Sep 30, 2021 | 1.57 Bn |